Search

Displaying results 4481 - 4490 of 10000 in total
  1. Drug

    KC706

    go.drugbank.com/drugs/DB05157
    Investigational

    KC706 is a novel anti-inflammatory drug that works by inhibiting the activity of p38 MAP kinase.

  2. Drug

    LY2275796

    go.drugbank.com/drugs/DB05165
    Investigational

    LY2275796 targets eukaryotic initiation factor- 4E (eIF-4E), a protein involved in the translation of key growth and survival factors that drive tumor progression, angiogenesis and metastases. … LY2275796 is a second-generation antisense anti-cancer drug candidate for clinical development.

  3. Drug

    IMC-1C11

    go.drugbank.com/drugs/DB06101
    Experimental

    It is a chimeric anti-kinase insert domain-containing receptor (KDR) antibody that blocks VEGFR-KDR interaction and inhibits VEGFR-induced endothelial cell proliferation. … IMC-1C11 is an anti-angiogenesis agent.

  4. Drug

    Nisin Z

    go.drugbank.com/drugs/DB19122
    Investigational

    Nisin Z is under investigation in clinical trial NCT06097468 (Nisin in Oral Cavity Squamous Cell Carcinoma (OCSCC)).

    Synonyms: Nisin a, 27-l-asparagine-, Nisin, 27-l-asparagine-Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    EHT899

    go.drugbank.com/drugs/DB05108
    Experimental

    It also apparently enhances a secondary immune response to clear the viral infection, resulting in reduction in liver damage and decrease in viral load. … EHT899 is a proprietary formulation of an HBV viral protein designed to eliminate the undesirable immune response elicited by the HBV infection.

  6. Drug

    Povidone K30

    go.drugbank.com/drugs/DB14478
    Approved

    A polyvinyl polymer of variable molecular weight; used as suspending and dispersing agent and vehicle for pharmaceuticals; also used as blood volume expander. See [povidone] for full details.

  7. Drug

    Peptide YY (3-36)

    go.drugbank.com/drugs/DB05004
    Investigational

    Peptide YY (3-36), a synthetic human PYY 3-36, is a compound being evaluated for the treatment of obesity. It reduces appetite and increases satiety in obese patients.

  8. Drug

    SAR-260301

    go.drugbank.com/drugs/DB33608
    Investigational

    Categories: Class Ia Phosphatidylinositol 3-Kinase, antagonists & inhibitors
  9. Drug

    Cimicoxib

    go.drugbank.com/drugs/DB05095
    Investigational

    If approved, Cimicoxib would be the first drug in decades to treat depression by a new mechanism of action. … Cimicoxib is a selective COX-2 inhibitor being developed by Affectis as a treatment for depression and schizophrenia.

  10. Drug

    NXN-188

    go.drugbank.com/drugs/DB06096
    Investigational

    NXN-188 is a first-in-class, dual-action small molecule incorporating both neuronal nitric oxide synthase (nNOS) inhibition and 5-HT agonism that is being developed for the treatment of acute migraine.